Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...
Patients do not conform to a one-size-fits-all implant model, especially when it comes to knee replacements. Off-the-shelf implants often leave room for improvement in terms of fit and comfort because ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results